Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO-incompatible haematopoietic stem cell transplantation

Research output: Contribution to journalLetter

9 Scopus citations
Original languageEnglish (US)
Pages (from-to)187-188
Number of pages2
JournalTransfusion Medicine
Volume24
Issue number3
DOIs
StatePublished - Jun 2014

Cite this